UCB and Amgen report positive data from osteoporosis drug trial

UCB and Amgen have announced the findings of a new clinical study showing the effectiveness of romosozumab, their new treatment for osteoporosis.

Results from the Phase III placebo-controlled FRAME study showed that the drug was able to reduce the incidence of new vertebral fractures through months 12 and 24 in postmenopausal women with osteoporosis.

This means it was able to meet its co-primary endpoints, as well as achieve the secondary goal of reducing the incidence of clinical fractures over 12 months.

Further analysis of the study data is ongoing and will be submitted to a future medical conference and for publication. The findings will also help to support future regulatory filings for the therapy.

Professor Dr Iris Loew-Friedrich, chief medical officer and executive vice-president of UCB, said: "Deeper understanding of the results will help us to sharpen the profile of romosozumab in postmenopausal women with osteoporosis."

This comes after the firms published results from another trial called STRUCTURE last year, showing the beneficial impact of romosozumab on hip bone mineral density.